Mast Cell Activation Syndrome (Q28261609)

Clinical Reviews in Allergy & Immunology

Europe PubMed Central

title

Mast Cell Activation Syndrome (English)

0 references

0 references

1 reference

Marianne Frieri

1

0 references

language of work or name

English

0 references

publication date

6 May 2015

0 references

published in

0 references

cites work

The high-affinity receptor for IgE.

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Association of protein-tyrosine kinase with phospholipase C-gamma 1 in bone marrow-derived mouse mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

c-kit ligand: a unique potentiator of mediator release by human lung mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Mast-cell responses in the development of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Evaluation of mast cell activation syndromes: impact of pathology and immunohistology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Stem cell factor programs the mast cell activation phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

The tyrosine kinase network regulating mast cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Mast cell activation syndrome: Proposed diagnostic criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Solitary mastocytoma of the eyelid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Malignant transformation of mastocytoma developed on skin mastocytosis into cutaneous mast cell sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Mast cell sarcoma of the scalp: The first sign of undisclosed systemic mastocytosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Causes and differential diagnosis of flush

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Mast Cell Activation Syndrome Masquerading as Agranulocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Sclerosing mediastinitis and mast cell activation syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Mast cell activation syndrome: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Pediatric Mastocytosis: A Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Immunology and clinical manifestations of non-clonal mast cell activation syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Spectrum of mast cell activation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Epidemiology, prognosis, and risk factors in mastocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Mechanisms of vitamin D₃ metabolite repression of IgE-dependent mast cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Clonal mast cell proliferation in pruriginous skin in hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

ERK1/2 antagonize AMPK-dependent regulation of FcεRI-mediated mast cell activation and anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Prostaglandin D2-supplemented "functional eicosanoid testing and typing" assay with peripheral blood leukocytes as a new tool in the diagnosis of systemic mast cell activation disease: an explorative diagnostic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Mast cell activation: a complex interplay of positive and negative signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

The more allergens an atopic patient is exposed to, the easier and quicker anaphylactic shock and Kounis syndrome appear: Clinical and therapeutic paradoxes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Stress triggers coronary mast cells leading to cardiac events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Utility of hydroxyurea in mast cell activation syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Mast cell activation syndrome as a significant comorbidity in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

The presence of mast cell clonality in patients with unexplained anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Britanin Suppresses IgE/Ag-Induced Mast Cell Activation by Inhibiting the Syk Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

Mast cell activation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-015-8487-6

The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others.

21 January 2018

1 reference

12 December 2020

Differential diagnosis of the patient with unexplained flushing/anaphylaxis.

1 reference

12 December 2020

Lymphadenopathic mastocytosis with eosinophilia and biclonal gammopathy

1 reference

12 December 2020

Increased interleukin-4 production in response to mast cell mediators and human type I collagen in patients with rheumatoid arthritis

1 reference

12 December 2020

Increased interleukin-2 production in response to human type I collagen stimulation in patients with systemic sclerosis

1 reference

12 December 2020

Stem cell factor (c-kit ligand) influences eosinophil recruitment and histamine levels in allergic airway inflammation

1 reference

12 December 2020

The kit ligand, stem cell factor

1 reference

12 December 2020

The c-kit receptor ligand functions as a mast cell chemoattractant

1 reference

12 December 2020

Cytokinergic IgE Action in Mast Cell Activation

1 reference

12 December 2020

Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report

1 reference

12 December 2020

Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab

1 reference

12 December 2020

The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis.

1 reference

12 December 2020

Idiopathic anaphylaxis

1 reference

12 December 2020

Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease

1 reference

12 December 2020

Mast cell involvement in rheumatoid arthritis

1 reference

12 December 2020

Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM).

1 reference

12 December 2020

Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management

1 reference

12 December 2020

Systemic sclerosis. The role of the mast cell and cytokines

1 reference

12 December 2020